問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare (在職)

Division of General Internal Medicine

Division of Thoracic Medicine

Division of Hematology & Oncology

Linkou Chang Gung Medical Foundation (在職)

Division of Hematology & Oncology

Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F. (在職)

Division of Hematology & Oncology

更新時間：2023-09-19

謝燿宇Hsieh, Yao-Yu
  • Principal Investigator
  • Clinical Trial Experience (year) -13 years -4 個月

Recruiting Trial

52Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

謝燿宇

List

92Cases

2020-07-01 - 2026-12-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
8Sites

Recruiting8Sites

2020-10-15 - 2026-12-31

Phase I/II

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
8Sites

Recruiting7Sites

2017-11-01 - 2020-03-19

Phase II/III

Completed
A Phase II/III, Randomised, Multicentre Study of MOR00208 with Bendamustine versus Rituximab with Bendamustine in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) Who Are Not Eligible for High-Dose Chemotherapy (HDC)and Autologous Stem-Cell Transplantation (ASCT) – B-MIND

  • Condition/Disease

    Diffuse Large B-cell Lymphoma

  • Test Drug

    MOR00208

Participate Sites
11Sites

Not yet recruiting7Sites

Terminated3Sites

白禮源
China Medical University Hospital-Taipei

未分科

2026-07-26 - 2029-10-29

Phase III

Not yet recruiting
A phase III, double-blind, placebo-controlled, randomized trial was conducted to evaluate the efficacy and safety of ASP3082 combined with mFOLFIRINOX or NALIRIFOX as first-line treatment in participants with KRAS G12D-mutant metastatic pancreatic adenocarcinoma.

  • Condition/Disease

    Metastatic pancreatic adenocarcinoma

  • Test Drug

    "Xinghui" Xingrui Platinum Intravenous Injection 5 mg/mL ASP3082 Haofu Injection 50 mg Anengde Liposome Injection Kefeiyan Injection 10 mg Anticancer Intravenous Concentrate Erenodin Concentrate Injection Fulinya Injection 10 mg/mL Yilinuo Intravenous Infusion Solution Yile Platinum Injection 5 mg/mL

Participate Sites
5Sites

Not yet recruiting1Sites

Recruiting4Sites

2022-10-01 - 2026-12-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
8Sites

Not yet recruiting3Sites

Recruiting4Sites

2023-04-01 - 2026-03-31

Phase I

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Recruiting1Sites

Terminated5Sites

2023-06-30 - 2029-02-28

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
10Sites

Not yet recruiting9Sites

2023-07-01 - 2031-11-06

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
12Sites

Recruiting12Sites

2023-07-31 - 2029-02-28

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
12Sites

Recruiting12Sites

2024-07-31 - 2031-12-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Recruiting7Sites

1 2 3 4 5 10
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB